Magenta Therapeutics, Inc.
MGTA
NASDAQ
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.32M | 6.13M | 5.94M | 6.05M | 6.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -32.00K | -- | -- | -- | -- |
| Total Operating Expenses | 5.43M | 14.13M | 21.73M | 17.25M | 18.08M |
| Operating Income | -5.43M | -14.13M | -21.73M | -17.25M | -18.08M |
| Income Before Tax | -3.28M | -29.17M | -20.18M | -16.06M | -17.27M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.28M | -29.17M | -20.18M | -16.06M | -17.27M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.28M | -29.17M | -20.18M | -16.06M | -17.27M |
| EBIT | -5.43M | -14.13M | -21.73M | -17.25M | -18.08M |
| EBITDA | -5.43M | -13.71M | -21.27M | -16.78M | -17.61M |
| EPS Basic | -0.87 | -7.70 | -5.33 | -4.34 | -4.70 |
| Normalized Basic EPS | -0.22 | -1.84 | -3.33 | -2.71 | -2.94 |
| EPS Diluted | -0.87 | -7.70 | -5.33 | -4.34 | -4.70 |
| Normalized Diluted EPS | -0.22 | -1.84 | -3.33 | -2.71 | -2.94 |
| Average Basic Shares Outstanding | 3.79M | 3.79M | 3.79M | 3.70M | 3.68M |
| Average Diluted Shares Outstanding | 3.79M | 3.79M | 3.79M | 3.70M | 3.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
